Cargando…
How zoledronic acid improves osteoporosis by acting on osteoclasts
Osteoporosis is called a silent disease, because it is difficult to detect until comprehensive examinations for osteoporosis are performed or osteoporotic fractures occur. Zoledronic acid is currently the first-line anti-osteoporotic drug, with good efficacy and treatment compliance. A major advanta...
Autores principales: | Wang, Biao, Zhan, Yi, Yan, Liang, Hao, Dingjun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452720/ https://www.ncbi.nlm.nih.gov/pubmed/36091799 http://dx.doi.org/10.3389/fphar.2022.961941 |
Ejemplares similares
-
Identifying therapeutic biomarkers of zoledronic acid by metabolomics
por: Li, Xiang, et al.
Publicado: (2023) -
Cost-Effectiveness of Sequential Denosumab/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China
por: You, Ruxu, et al.
Publicado: (2022) -
Effect of Denosumab on the Change of Osteoclast Precursors Compared to Zoledronate Treatment in Postmenopausal Women with Osteoporosis
por: Kong, Sung Hye, et al.
Publicado: (2022) -
Minimally effective concentration of zoledronic acid to suppress osteoclasts in vitro
por: Li, Pengfei, et al.
Publicado: (2018) -
Role of zoledronic acid in the prevention and treatment of osteoporosis
por: Räkel, Agnès, et al.
Publicado: (2011)